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Abstract
perfluorocarbon compounds are fluorine substituted hydrocarbons. they exhibit unique 
properties due to the specificity of the carbon –fluorine linkage. Among these, the high 
gas solubility and the low surface tension are the most interesting characteristics for their 
use in clinic. there are several biological fields of potential applications of perfluorocarbons. 
concerning the clinical applications for perfluorocarbons, they have been used as gas 
carriers and for liquid ventilation. Several clinical trials for commercial pharmaceutics of 
perfluorcarbon based on these compounds have been also already made.
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Resumo
os compostos perfluorados são análogos aos hidrocarbonetos mas onde a ligação carbono-
hidrogénio (c-H) é substituída pela ligação carbono-flúor (c-F). A ligação c-F confere 
propriedades aos compostos perfluorados que são diferentes das dos hidrocarbonetos que 
lhes são análogos. A capacidade de dissolução de elevadas quantidades de gases e a baixa 
tensão superficial apresentam são propriedades que têm levado ao desenvolvimento da 
investigação aplicada, baseada nestes compostos. relativamente à parte clínica, alguns deles 
têm sido ensaiados com sucesso como “substituintes do sangue”, no sentido em podem ser 
utilizados com veículos distribuição de gases na circulação, e como líquidos adjuvantes da 
ventilação pulmonar, em casos de existência de obstruções pulmonares graves. 
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60 1. INTRODUCTION
perfluorocarbons, pFc’s, are linear, cyclic or polycyclic fluorine substituted hydrocarbons.
in the last 20 years fluorine chemistry and perfluorocarbon compounds have been an 
important field of research. the perfluorocarbons properties and applications have been 
investigated by researchers in several areas like biophysics, biochemistry, pharmacology, 
engineering and biotechnology and clinics. clinical trials of some pharmaceuticals have 
already been made, some of which are already in phase ii/iii trials. Due to their unique 
properties, pure pFc’s or fluorocarbon in water emulsions have a promising wide utilization 
in biomedical field, from artificial liquid ventilation to oxygen carriers as blood substitutes, 
passing through to their uses in controlled release drug delivery (lowe, k.c., 2006), (krafft, 
m. p., 2001). the inertness of pFc’s allied to the capacity of dissolving great amounts of gases 
(riess, j.g., 2001)) are the main properties that make pFc’s a selected group of compounds 
for utilization in gas delivery therapeutics.
the use of pFc’s as ventilator liquids have some advantages in patients with chronic 
obstruction once the problem allied to surface tension air/liquid aspects are minimized, but 
the biggest future application could be in blood cell substitution in acute loss of blood.
blood transfusion in developed countries is a very safe clinical procedure, but it is not a 
zero-risk intervention: allogenic donors can cause haemolytic reactions. Also, the need to 
minimise the risk of transmission of prions, the emergence of human immunodeficiency 
virus among others, are effective risks that are allied to this classic technique. in fact, artificial 
blood carriers, such as perfluoroalcanes, have been identified as a good answer for replacing 
acute blood loss during surgery or following trauma and for treatment of patients who 
refuse blood transfusions for clinical or religious reasons, (Fratantoni, j.c., 1998). 






































61in spite of the general inertness and the high vapour gases partial pressures, not all pFc’s 
are of interest for biological and economical evaluation. the most interesting pFc’s for 
biological uses are presented in Figure 1. the biological use is conditioned by the molecular 
weight of the compounds (from ca of 460 to 520 g.mol-1). the most used in formulations 
are perfluorodecalin and perfluorobron (bromoperfluoro-n-octane) (riess, j.g., 2001).  the 
biocompatibility of these compounds is already assured. this means that they can be 
obtained with high purity level, have the ability to form stable emulsions, present rapid 
excretion rate and absence of side effects of the product or metabolic sub-products. Also, 
the cost of effective industrial production is low.
2. PHySICAL AND CHEMICAL ASPECTS OF PFC’S
2.1. GENERAL ASPECTS
in perfluorocarbons compounds, the hydrogen atoms of a linear, cyclic or polycyclic 
hydrocarbon are replaced by fluorine atoms. the fluorine atom is more electronegative than 
the hydrogen atom and its volume size is significantly larger (Van der Waals radius is 1.20 Å 
for H and 1.47 Å for F). these differences allow the covalent bond between the element and 
carbon atom to have quite different physical chemical properties. pFc’s are much more inert 
than their similar hydrocarbons. the thermal and chemical stability may arise from the c-F 
bond strength (~485 kj mol-1) as compared to the c-H one (~425 kj.mol-1). the stability of 
the c-F single bond maybe due to the effective overlapping of the sp3 carbon atom orbital 
with the p fluorine atom orbital. the biological and biochemical inertness results from the 
repellent effect that the electronic cloud of fluorine exerts against reagent approaches.
the volume size of perfluoroalkanes is approximately one and a half times bigger when 









 the same values are 27 Å3 and 54 
Å3, respectively. the perfluoride chains assume a great stiffness, probably due to the loss of 
the cis/trans freedom of rotation which alkenes have. these allow the perfluorinated chains 
to adopt a helical conformation in order to minimize steric effects (H. Hoffmann, H & all, 
1983); (eaton, D. F. & Smart, b. e., 1990); (gruen, D.W.r., 1985). the differences in conformation 
between alkenes and perfluoroalkenes are exemplified in Figure 2 with the seven carbon 
atoms compounds. 
Figure 2 - Differences in conformation between hydrocarbons and perfluorocarbons. these differences are here 
exemplified with the 7 carbon atom molecules. top: n-heptane. button: perfluoro-n-heptane. the molecules were 
geometrically optimized using g03W at b3lyp/6311++g(d,p) level of theory (Freire, m.g. 2006).
lateral View top view
62 the fluorine atom has a low polarizability so the Van der Waals interactions between their 
chains are weak leading to low cohesive energies in liquids. this characteristic can explain 
the observed properties of pFc’s, like low surface tension values, high spread values, high 
fluidity, high vapour pressures and high gas solubility. 






. the solubility of oxygen in pFc 
liquids at 37 ºc and 1 atm used in biomedical applications is of about 40 to 50% (v/v) while 
for co
2 
this percentage rises to about 200% (v/v). table 1 gives the solubility values for the 
most used compounds in biological systems (riess, j. g., 2001).
Table 1 - Solubility of oxygen and carbon dioxide and organ half-life values for some of perfluorocarbons used in clinic.
Molecular Formula
Solubility O2  
(% v/v at 37 ºC)
Solubility CO2  
(% v/v at 37 ºC)



































perfluorocarbons and the effects of substitution of the fluoride atoms by other halogens. 
the substitution of a fluoride atom by a bromide or chloride causes a slight decrease in the 
solubility of dioxygen and a significantly increase of the solubility of carbon dioxide (costa 
gomes m. F & al., 2004), Deschamps, j. & al., 2007). 
the gas content in the liquid is proportional to the gas phase pressure given by Henry’s 
law. relative to oxygen, that linear relation contrasts with the sigmoid relationship between 
oxygen content and oxygen partial pressure for haemoglobin. the dioxygen concentration 
in pFc pharmaceuticals can be increased by increasing the dioxygen concentration in the 
inspired air of the patient. Due to the weak interaction between the solvent and solute in 
pFc, the release of o
2
 to the tissue is greatly facilitated, giving extraction rates of typically 90% 
that are higher than the allow by the dissociation o
2
-Fe process that occurs in Haemoglobin 
(typically 25-30%) (keipert, p.e., 1996).
2.2. EMULSION PREPARATIONS
pFc’s are immiscible in water, so a preparation for injection must be oil in water emulsion or 
a reverse one, when the preparations are to be used for drug delivery. concerning emulsion 
preparations companies had to solve two main problems: the monitoring of the target drop 
diameter and the emulsifier agent.
63Droplet emulsion size should lie within the 0.1-0.2 µm range. the main problem arising from 
the control of the drop size is the “ostwald ripening”. this is due to the fact that individual 
fluorocarbon molecules leave the smaller droplets to join the larger ones, thus increasing 
the volume of the particles. the interfacial tension conditions the largest upper pressure 
which the smaller drops have compared to the larger ones, driving the force to the ripening. 
the speed of the increment of the drop size is then dependent on the diffusibility and 
solubility of pFc in water or vice-versa. the solubility of water in pFc seems to increase with 
the carbon number of the solvents. this could be because larger molecules can more easily 
accommodate a molecule of solute, increasing its solubility. it has also been shown that the 
solubility of water in the α-(ω-) substituted fluorocarbons is increased by the inclusion of br 
atoms (Freire, m.g. & all, 1996).
Several substances have been tried as emulsifier agents. the most effective surfactant sys-
tem, without clinical side effects, is the equimolar amounts of egg yolk phospholipids and 
mixed fluorocarbon/hydrocarbon amphiphile. 
3. CLINICAL APPLICATIONS AS GAS CARRIERS
these compounds have been studied as biological gas carriers since the sixties. First, they 
have been studied by their possible uses in liquid ventilation. liquid ventilation eliminates 
the gas-liquid interface reducing the alveolar surface tension. this improves the lung com-
pliance and lung oxygenation. this characteristic is particularly important when there is in-
sufficiency of surfactant.
biomedical research has been made in liquid ventilation of premature babies with respira-
tory disease (greenspan , j. S. & all , 2000). this has been tried in the treatment of the respi-
ratory distress syndrome:  for this proposes, the compound is installed in the lungs of the 
patient during the treatment. For temporary blood substitution the fluorocarbon must be 
an injectable emulsion.
concerning the oxygen distribution in blood the effective biomedical application had to 
wait for the advance in biotechnology of formulations. Droplet emulsion size lies within the 
0.1-0.2 µm range. this is 30-70 times smaller than blood cells. emulsion drops can thus be 
much more numerous than red blood cells and can be present in the plasma gaps between 
erythrocytes in the microcirculation structures. this can be very valuable for o
2
 supply to the 
cells during acute anaemia or hemodilution. the high po
2 
provides a strong driving force 
for dioxygen diffusion to the tissue. the same phenomenon happens with co
2
 but in the 
reverse way.
there are several commercial pharmaceuticals of pFc-based oxygen carriers that have been 
in clinical trials.
Fluosol® (green cross and Alpha therapeutic) was an emulsion of two main components 
(perfluorodecalin and perfluorotripropylamine, approved in 1990 in the uSA and some 
european countries. this association was used for the oxygenation of heart tissue during 
angioplasty and to preserve human organs prior to transplantation. the production ceased 
in 1994 since the maximum oxygen carrier capacity was significantly lower than that of Hb 
(k. c. lowe, 2005).
64 perftoran® (russian Academy of Sciences and perftoran company) was a two component 
pFc with perfluorodecaline and perfluoromethylcyclopiperidine. it was introduced in 1996 
in russia as an alternative anti-ischaemic agent and for the preservation of perfuse organs 
for transplantation. it has been used in several patients in russia and ukraine (maevsky, k. e. 
& all, 2005).
oxygent tm (Alliance pharmaceutical uSA). oxygent tm has two perfluorcarbons in the for-
mulation: perfluorodecyl bromide and perflubron. the emulsion was stabilised with egg 
phospholipids (keipert, p.e., 2005). this formulation had a higher stability than the previous 
ones ( more than one year at 5-10 ºc and the total amount of oxygen carrier capacity was 
significantly higher than the previous ones, since the pFc content of the formulations was 
of about 60% (v/v) compared with 20% (v/v) in the others). it has been tried as oxygenation 
fluid in cases of high blood losses surgeries such orthopaedic ones. it was shown that the 
use of oxygent tm reduces the frequency and the volume of blood use during surgery (Fru-
mento, j. r., 2002). For some time the company suspended the phase iii trial in order to eval-
uate the effect of the use of the pharmaceutical in the stroke that was noted in the patients 
that could be due to the pre-surgical acute normovolaemic heamodilution protocol (niller, 
e., 2002). Anyhow, in 2005 the product was licensed again in china, europe and canada.
other pFc’s pharmaceuticals
nowadays there are some new products in phase i or ii of trials like for instances, ocycytetm 
for prevention of tissue hypoxia during orthopaedic and cardiac surgery. 
4. METABOLISM AND TOXICITy
the molecules are sequestered by phagocyte cells of the monocyte /macrophage system. 
they diffuse back to the blood where they are carried in plasma lipids to the lungs and then 
exhaled as vapour (riess, j. g., 2001, 2005).
the lD50 for Furosol® is of ~25g/kg of body (okamoto, H., 1973) and for oxygent tm is about 
54 g/ kg body (Flaim, S. F., 1994). Side effects that had been reported in some volunteers con-
sisted of early effects like headache and, occasional lower backache. Delayed effects (2-12 h) 
consisted of fever, chills and nausea. these effects were fully reversible within 12-24 h. it has 
been shown that these effects were related to the normal circulations clearance process for 
emulsions. the phagocytation of the emulsion droplets can activate the macrophages and 
release products of the arachidonic acid cascade (Flaim, S. F., 1994).
5. FINAL REMARKS
the research concerning the perfluoroalkenes and their applications is still in a growing 
phase. concerning biomedicine and bioengineering we can find that there are several 
working groups all over europe, north and South America, india and japan that are invest-
ing their resources in this field. We expect new incomings and applications in the clinical 
and medical area.
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